TMCnet - World's Largest Communications and Technology Community



Research and Markets: Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
[May 19, 2014]

Research and Markets: Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering.

In 2012, Newron completed Phase III clinical trials for safinamide, a dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck Serono (a division of Merck KGaA) had acquied the exclusive worldwide rights for safinamide; however, in 2011 the deal was terminated, seeing Merck returning the compound to Newron due to concerns over the potential market size for the drug.


  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Safinamide including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Safinamide for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Safinamide

9 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy